KDM6A and neoplasm: In a mouse model, treatment with a CXCL1-neutralizing antibody blocked the chemotactic and NET-promoting properties of KDM6A-deficient PDAC cells and suppressed tumor growth, highlighting its potential as a targeted treatment strategy.